Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 16, 2013 08:57 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Notified That FDA Will Not Meet the PDUFA Action Date for Ravicti(TM)

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) said that the U.S. Food and Drug Administration (FDA) has advised the Company not to expect a...
November 12, 2012 09:18 ET | Source: Hyperion Therapeutics, Inc.

HALT-HE Study Underscores Role of Ammonia in Hepatic Encephalopathy

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that the results of the Phase 2 HALT-HE Study were presented at the...
November 07, 2012 16:09 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Announces Third Quarter 2012 Operating Results

SOUTH SAN FRANCISCO, Calif., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (NasdaqGM:HPTX) today reported consolidated financial results for the third quarter of 2012. According to...
November 05, 2012 14:49 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics to Present at Upcoming Investor Conferences in November

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at two investor conferences in...
October 17, 2012 16:30 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics to Host/Webcast Analyst and Investor Briefing at AASLD

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that the company will host and webcast an analyst and investor briefing on...
October 02, 2012 18:56 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics to Report Results of HALT-HE Study at AASLD Plenary Session

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that the results of the HALT-HE Study will be presented at the 63rd Annual...
September 06, 2012 16:05 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Announces Second Quarter 2012 Operating Results

SOUTH SAN FRANCISCO, Calif., Sept. 6, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported consolidated financial results for the second quarter of 2012. The company...
September 05, 2012 17:39 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Announces Extension of Action Date for Ravicti(TM) NDA to January 23, 2013

SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that it has received a communication from the U.S. Food and Drug Administration...
August 28, 2012 16:00 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Appoints Daniel G. Welch to Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that it has named Daniel G. Welch to its Board of Directors. Mr. Welch currently...
August 21, 2012 16:05 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics to Present at the 19th Annual Newsmakers in the Biotech Industry Conference

SOUTH SAN FRANCISCO, Calif., Aug. 21, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the BioCentury and Thomson Reuters 19th...